NTLA - Intellia Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
NTLA price evolution
NTLA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $130.85 | $171.98 | $226.75 | |
| Short term investments | $560.22 | $619.32 | $685.48 | |
| Net receivables | $8.85 | $12.33 | $36.43 | $36.46 |
| Inventory | ||||
| Total current assets | $710.9 | $757.21 | $884.04 | $998.33 |
| Long term investments | $298.64 | $233.05 | $154.51 | |
| Property, plant & equipment | $129.09 | $135.69 | $142.5 | $148.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $434.32 | $375.55 | $302.65 | |
| Total investments | $858.86 | $852.36 | $839.99 | |
| Total assets | $1173.35 | $1191.54 | $1259.59 | $1300.98 |
| Current liabilities | ||||
| Accounts payable | $13.14 | $18.82 | $13.69 | $7.45 |
| Deferred revenue | $50.24 | $55.62 | $60.99 | |
| Short long term debt | $18.96 | $18.76 | $18.6 | |
| Total current liabilities | $105.68 | $105.09 | $97.91 | $115.21 |
| Long term debt | $87.33 | $92.1 | $96.75 | |
| Total noncurrent liabilities | $115.38 | $125.54 | $135.6 | |
| Total debt | $106.3 | $110.86 | $115.35 | |
| Total liabilities | $210.74 | $220.47 | $223.45 | $250.81 |
| Shareholders' equity | ||||
| Retained earnings | -$2048.5 | -$1912.79 | -$1765.82 | -$1658.38 |
| Other shareholder equity | $3.3 | -$1.16 | -$0.95 | -$2.26 |
| Total shareholder equity | $971.06 | $1036.14 | $1050.17 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $226.75 | $523.51 | $123.41 | $160.02 |
| Short term investments | $685.48 | $669.12 | $625.28 | $437.35 |
| Net receivables | $36.46 | $3.77 | $2.03 | $2.13 |
| Inventory | ||||
| Total current assets | $998.33 | $1216.8 | $769.3 | $616.52 |
| Long term investments | $154.51 | $142.32 | $425.05 | |
| Property, plant & equipment | $148.13 | $161 | $100.11 | $55.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $302.65 | $303.32 | $525.16 | $59.8 |
| Total investments | $839.99 | $811.44 | $1050.33 | $437.35 |
| Total assets | $1300.98 | $1520.11 | $1294.46 | $676.32 |
| Current liabilities | ||||
| Accounts payable | $7.45 | $5.15 | $9.65 | $10.46 |
| Deferred revenue | $60.99 | $63.77 | $127.23 | $73.93 |
| Short long term debt | $18.6 | $16.68 | $9.11 | $5.7 |
| Total current liabilities | $115.21 | $126.55 | $125.83 | $64.25 |
| Long term debt | $96.75 | $114.02 | $64.91 | $33.61 |
| Total noncurrent liabilities | $135.6 | $157.98 | $128.39 | $85 |
| Total debt | $115.35 | $130.7 | $74.02 | $39.3 |
| Total liabilities | $250.81 | $284.53 | $254.22 | $149.25 |
| Shareholders' equity | ||||
| Retained earnings | -$1658.38 | -$1177.19 | -$703 | -$435.11 |
| Other shareholder equity | -$2.26 | -$7.46 | -$2.63 | $0 |
| Total shareholder equity | $1050.17 | $1235.58 | $1040.24 | $527.07 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.11 | $6.96 | $28.93 | -$1.92 |
| Cost of revenue | ||||
| Gross Profit | $6.96 | $28.93 | -$1.92 | |
| Operating activities | ||||
| Research & development | $114.21 | $111.85 | $108.98 | |
| Selling, general & administrative | $31.79 | $31.09 | $28.99 | |
| Total operating expenses | $153.88 | $146 | $142.94 | $137.97 |
| Operating income | -$139.04 | -$114 | -$139.89 | |
| Income from continuing operations | ||||
| EBIT | -$146.97 | -$107.44 | -$132.16 | |
| Income tax expense | ||||
| Interest expense | $9.06 | |||
| Net income | ||||
| Net income | -$135.71 | -$146.97 | -$107.44 | -$132.16 |
| Income (for common shares) | -$146.97 | -$107.44 | -$132.16 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.27 | $52.12 | $33.05 | $57.99 |
| Cost of revenue | ||||
| Gross Profit | $36.27 | $52.12 | $33.05 | $57.99 |
| Operating activities | ||||
| Research & development | $435.07 | $419.98 | $229.81 | $150.41 |
| Selling, general & administrative | $116.5 | $90.31 | $71.1 | $44.17 |
| Total operating expenses | $551.57 | $510.29 | $300.9 | $194.58 |
| Operating income | -$515.29 | -$458.16 | -$267.85 | -$136.58 |
| Income from continuing operations | ||||
| EBIT | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Income (for common shares) | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$146.97 | -$107.44 | -$132.16 | |
| Operating activities | ||||
| Depreciation | $2.6 | $2.51 | $2.47 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $40.86 | $34.18 | $35.04 | |
| Total cash flows from operations | -$58.19 | -$120.66 | -$93.05 | |
| Investing activities | ||||
| Capital expenditures | -$1.01 | -$2.51 | -$1.52 | |
| Investments | -$23.18 | $8.41 | $47.46 | |
| Total cash flows from investing | -$26 | -$24.19 | $5.9 | $45.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $39.58 | $59.99 | $104.61 | |
| Net borrowings | ||||
| Total cash flows from financing | $183.43 | $41.25 | $59.99 | $106.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$106.25 | -$41.13 | -$54.77 | $59.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Operating activities | ||||
| Depreciation | $8.98 | $7.57 | $6.89 | $6.31 |
| Business acquisitions & disposals | -$44.83 | -$3 | ||
| Stock-based compensation | $134.05 | $91.4 | $47.01 | $19.9 |
| Total cash flows from operations | -$394.09 | -$333.29 | -$225.03 | -$49.91 |
| Investing activities | ||||
| Capital expenditures | -$13.98 | -$13.41 | -$12.76 | -$3.58 |
| Investments | -$17.36 | $218.55 | -$535.02 | -$210.9 |
| Total cash flows from investing | -$31.35 | $160.31 | -$550.78 | -$214.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $126.39 | $580.31 | $734.66 | $370.22 |
| Net borrowings | ||||
| Total cash flows from financing | $130.32 | $582.96 | $736.69 | $371.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$295.11 | $409.98 | -$39.12 | $107.38 |
News
Fundamentals
| Market cap | $1.42B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 101.80M |
| Revenue | $43.09M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$522.28M |
| Revenue Q/Q | -24.02% |
| Revenue Y/Y | -16.77% |
| P/E ratio | -2.72 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 32.98 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$5.13 |
|---|---|
| ROA | -42.42% |
| ROE | N/A |
| Debt/Equity | 0.24 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.73 |
| Quick ratio | N/A |